DK0495421T3 - Anvendelse af carragenaner i topiske ophthalmiske sammensætninger - Google Patents

Anvendelse af carragenaner i topiske ophthalmiske sammensætninger

Info

Publication number
DK0495421T3
DK0495421T3 DK92100423.0T DK92100423T DK0495421T3 DK 0495421 T3 DK0495421 T3 DK 0495421T3 DK 92100423 T DK92100423 T DK 92100423T DK 0495421 T3 DK0495421 T3 DK 0495421T3
Authority
DK
Denmark
Prior art keywords
carrageenans
compositions
topical ophthalmic
ophthalmic compositions
relates
Prior art date
Application number
DK92100423.0T
Other languages
English (en)
Inventor
John C Lang
Paul Joseph Tracy Missel
Jamieson C Keister
Dimitri James Stancioff
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of DK0495421T3 publication Critical patent/DK0495421T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK92100423.0T 1991-01-15 1992-01-13 Anvendelse af carragenaner i topiske ophthalmiske sammensætninger DK0495421T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64121491A 1991-01-15 1991-01-15

Publications (1)

Publication Number Publication Date
DK0495421T3 true DK0495421T3 (da) 1996-12-09

Family

ID=24571428

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92100423.0T DK0495421T3 (da) 1991-01-15 1992-01-13 Anvendelse af carragenaner i topiske ophthalmiske sammensætninger

Country Status (7)

Country Link
US (1) US5403841A (da)
EP (1) EP0495421B1 (da)
JP (1) JP2594486B2 (da)
AT (1) ATE141502T1 (da)
CA (1) CA2059403C (da)
DE (1) DE69212850T2 (da)
DK (1) DK0495421T3 (da)

Families Citing this family (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2129037C (en) * 1992-02-21 1998-03-24 Thomas Robert Dean Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
JPH08501303A (ja) * 1992-09-17 1996-02-13 アルコン ラボラトリーズ，インコーポレイテッド 局所用炭酸脱水酵素阻害剤組成物
SE9301877D0 (sv) * 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997018812A1 (en) * 1995-11-17 1997-05-29 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
CH690814A5 (it) * 1996-11-04 2001-01-31 Applied Pharma Res Composizioni per uso topico contenenti polisaccaridi solfati.
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US6462080B1 (en) 1998-12-24 2002-10-08 Alcon Manufacturing, Ltd. Prostaglandin E receptor agonists for treatment of dry eye
US6544975B1 (en) 1999-01-25 2003-04-08 National Jewish Medical And Research Center Substituted porphyrins
ES2199873T3 (es) 1999-11-01 2004-03-01 Alcon Inc. Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma xantan.
WO2001034550A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
PT1237549E (pt) 1999-11-09 2004-06-30 Alcon Inc Lipoxina a4 e seus analogos para o tratamento de olho seco
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
WO2001034615A1 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
JP2003513946A (ja) 1999-11-09 2003-04-15 アルコン，インコーポレイテッド ω鎖修飾１５−ヒドロキシエイコサテトラエン酸誘導体、ドライアイの処置のためのそれらの使用方法
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
PT1228028E (pt) 1999-11-09 2005-10-31 Alcon Inc Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
DK1228026T3 (da) 1999-11-09 2004-04-05 Alcon Inc 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
EP1228030B1 (en) 1999-11-09 2005-06-01 Alcon Inc. Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders
PL355998A1 (en) 1999-11-09 2004-05-31 Alcon Inc. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6331644B1 (en) 1999-11-09 2001-12-18 Alcon Universal Ltd. 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use
WO2001034553A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
PL356092A1 (en) 1999-11-09 2004-06-14 Alcon Inc. Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
AU2603301A (en) 1999-12-22 2001-07-03 Alcon Universal Limited 6-keto prostaglandin F1alpha and analogs for treating dry eye
BR0112787B1 (pt) 2000-07-28 2013-03-05 composiÇço de soluÇço topicamente administrÁvel.
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US20030060447A1 (en) * 2002-04-24 2003-03-27 Mutlu Karakelle Non-aspirating transitional viscoelastics for use in surgery
WO2002040056A2 (en) 2000-11-06 2002-05-23 Alcon, Inc Carrageenan viscoelastics for ocular surgery
JP2004531560A (ja) * 2001-05-21 2004-10-14 アルコン，インコーポレイテッド ドライアイ障害を処置する方法
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
DE60213230T2 (de) 2001-05-21 2006-11-23 Alcon Inc. Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
JP2004530699A (ja) 2001-05-21 2004-10-07 アルコン，インコーポレイテッド ドライアイ障害を処置するためのプロテオソームインヒビターの使用
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
US6750250B1 (en) 2001-07-12 2004-06-15 Alcon, Inc. 11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
US20040220089A1 (en) * 2001-10-03 2004-11-04 Ellis Edward J. Ophthalmic preparation containing glycoprotein
US20040214754A1 (en) * 2001-10-03 2004-10-28 Ellis Edward J. Ophthalmic preparation containing glycomacropeptide
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
CA2464736A1 (en) * 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2477049A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
JP2005521690A (ja) * 2002-02-22 2005-07-21 ファルマシア・コーポレーション ゴム系を含む眼科用製剤
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
WO2004060274A2 (en) * 2002-12-20 2004-07-22 Alcon, Inc. Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
US7659289B2 (en) * 2004-09-17 2010-02-09 Comentis, Inc. Hydroxyethylene-based β-secretase inhibitors and use thereof
US20080207527A1 (en) * 2004-09-17 2008-08-28 Comentis, Inc. Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
JP2008535863A (ja) * 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
WO2008005457A2 (en) 2006-06-30 2008-01-10 Sunesis Pharmaceuticals Pyridinonyl pdk1 inhibitors
CA2673137C (en) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
HUE043228T2 (hu) 2007-06-22 2019-08-28 Univ Texas Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
KR20100051668A (ko) * 2007-07-26 2010-05-17 코멘티스, 인코포레이티드 베타-세크레타제 활성을 억제하는 이소프탈아미드 유도체
CN101868457B (zh) * 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
JP2011513393A (ja) * 2008-03-07 2011-04-28 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド 眼用組成物
ES2464728T3 (es) 2008-05-23 2014-06-03 National Jewish Health Compuestos para su uso en el tratamiento de lesiones asociadas con la exposición a una especie química alquilante
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8618096B2 (en) * 2008-07-21 2013-12-31 The Regents Of The University Of California Prodrug compositions and methods for using the same in treating cancer and malaria
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
CA2746810C (en) 2008-12-30 2017-03-14 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
PT2389372E (pt) 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
MX2011008647A (es) * 2009-02-20 2011-10-28 Micro Labs Ltd Producto de prostaglandina de almacenamiento estable.
CN102470135A (zh) 2009-07-28 2012-05-23 里格尔药品股份有限公司 抑制jak途径的组合物和方法
EP2467142B1 (en) 2009-08-17 2016-09-21 Memorial Sloan-Kettering Cancer Center 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders
EP2473049B1 (en) 2009-09-04 2018-11-28 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
PT2485731T (pt) 2009-10-06 2016-08-17 Millennium Pharm Inc Compostos heterocíclicos úteis como inibidores de pdk1
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
AU2010315561B2 (en) 2009-10-26 2016-10-20 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
WO2011060440A2 (en) 2009-11-16 2011-05-19 The Regents Of The University Of California Kinase inhibitors
ME02194B (me) 2009-12-10 2016-02-20 Univ California Agensi koji vežu amiloid
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
KR102113960B1 (ko) 2010-03-30 2020-05-21 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
SI2563771T1 (sl) 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
CN103201280B (zh) 2010-07-28 2016-08-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
BR112013011830B1 (pt) 2010-11-13 2022-03-15 Innocrin Pharmaceuticals, Inc Composto inibidor de metaloenzima, composição que compreende o dito composto, bem como uso do mesmo para tratar uma doença ou transtorno relacionado à metaloenzima
EP2651905B1 (en) 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
EP2675786B1 (en) 2011-02-14 2018-12-26 Allergan, Inc. Ester derivatives of bimatoprost compositions and methods
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
EP3682896A1 (en) 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
EP2721022B1 (en) 2011-06-19 2019-03-06 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
KR101912850B1 (ko) 2011-06-19 2018-10-30 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
EA025266B1 (ru) 2011-06-23 2016-12-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
EP2726097A4 (en) 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
CA2853729A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
DK2788343T3 (da) 2011-12-11 2018-06-14 Viamet Pharmaceuticals Nc Inc Metalloenzyminhibitorforbindelser
CN104136427B (zh) 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
WO2013142038A2 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
CA2913736A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Compounds and methods of treating cancer
KR20200110820A (ko) 2012-08-27 2020-09-25 알레간 인코포레이티드 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
SI3181567T1 (sl) 2012-09-10 2019-09-30 Principia Biopharma Inc. Spojine pirazolopirimidina, kot inhibitorji kinaze
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
CA2900335C (en) 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
US9364462B2 (en) 2012-10-30 2016-06-14 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
AU2014214561C1 (en) 2013-02-11 2019-01-17 Mitokinin, Inc. Compositions and methods for treating neurodegenerative diseases
US9295665B2 (en) 2013-03-12 2016-03-29 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
US9321745B2 (en) 2013-03-12 2016-04-26 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid IP receptors
EP2968270A4 (en) 2013-03-14 2016-08-17 Univ California MODULATION OF K2P CHANNELS
CA2902914A1 (en) 2013-03-14 2014-09-25 City Of Hope 5-bromo-indirubins
AU2014236356A1 (en) 2013-03-14 2015-09-24 The Regents Of The University Of California Thiosaccharide mucolytic agents
PL2970346T3 (pl) 2013-03-15 2019-02-28 The Regents Of The University Of California Acykliczne diestry fosfonianowe nukleozydów
RU2015134772A (ru) 2013-03-15 2017-04-21 Аллерган, Инк. Применение биматопроста для повышения выработки лептина
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
CN110423221A (zh) 2013-03-15 2019-11-08 维颂公司 作为凝血酶抑制剂的卤代吡唑
WO2014146111A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
KR20150132148A (ko) 2013-03-15 2015-11-25 베르선 코포레이션 세린 프로타아제 억제제로서의 다중 치환된 방향족 화합물
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2949048A1 (en) 2013-05-22 2014-11-27 The Regents Of The University Of California Aurora kinase inhibitors
US9795691B2 (en) 2013-06-24 2017-10-24 City Of Hope Chemically-linked nanoparticles
AU2014290202B2 (en) 2013-07-15 2018-11-15 Board Of Regents, The University Of Texas System Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
EP3035926B1 (en) 2013-08-19 2020-07-29 The Regents of The University of California Compounds and methods for treating an epileptic disorder
JP2016530273A (ja) 2013-08-20 2016-09-29 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 癌を治療するためのｈｄａｃ８阻害剤
WO2015031799A1 (en) 2013-08-30 2015-03-05 The Regents Of The University Of California, A California Corporation Scintillator nanocrystal-containing compositions and methods for their use
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN108947913A (zh) 2013-12-11 2018-12-07 比奥根Ma公司 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
PT2898888T (pt) 2014-01-22 2019-07-16 Visufarma B V Composição que compreende iota-carragenina contra conjuntivite viral
WO2015116856A2 (en) 2014-01-29 2015-08-06 City Of Hope Farnesoid x receptor antagonists
EP3104706B1 (en) 2014-02-11 2022-03-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CA2937752C (en) 2014-02-14 2023-02-07 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
CA2939569A1 (en) 2014-02-20 2015-11-19 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
JP6473461B2 (ja) 2014-03-26 2019-02-20 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｂｒｃａ１欠損癌または耐性癌の治療
EP3988540A1 (en) 2014-04-07 2022-04-27 The Regents of the University of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
EP3143013B1 (en) 2014-05-13 2019-12-18 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
US10980744B2 (en) 2014-08-08 2021-04-20 The Regents Of The University Of California High density peptide polymers
JP6692798B2 (ja) 2014-09-11 2020-05-13 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ｍＴＯＲＣ１阻害剤
PT3194411T (pt) 2014-09-15 2022-06-06 Univ California Análogos de nucleótidos
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
AU2015327817B2 (en) 2014-10-02 2020-04-23 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
MX2017007973A (es) 2014-12-18 2018-02-09 Principia Biopharma Inc Tratamiento de penfigo.
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
SG11201705413WA (en) 2015-01-16 2017-08-30 Hope City Cell penetrating antibodies
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
CN107530326B (zh) 2015-02-25 2021-09-21 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
BR112017018198A2 (pt) 2015-02-27 2018-04-10 Curtana Pharmaceuticals Inc inibição da atividade de olig2
CA2977401A1 (en) 2015-02-27 2016-09-01 The Regents Of The University Of California Small molecules that enable cartilage rejuvenation
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CA2981504C (en) 2015-03-30 2023-10-24 City Of Hope Mechanically interlocking complexes
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
AU2016247858B2 (en) 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
WO2016172726A1 (en) 2015-04-24 2016-10-27 The Regents Of The University Of California Modulators of ror1-ror2 binding
ES2852973T3 (es) 2015-05-15 2021-09-14 Hope City Composiciones de receptores de antígeno quimérico
US10787664B2 (en) 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
WO2016201169A1 (en) 2015-06-10 2016-12-15 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
US10758624B2 (en) 2015-07-02 2020-09-01 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2811136T3 (es) 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
WO2017024238A1 (en) 2015-08-06 2017-02-09 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
US11136301B2 (en) 2015-08-31 2021-10-05 The Regents of the University of California, A California Corporation et al. Broad spectrum antiviral compounds and uses thereof
EP3350181B1 (en) 2015-09-02 2023-11-01 The Regents of The University of California Her3 ligands and uses thereof
JP6933644B2 (ja) 2015-09-04 2021-09-08 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ アンドロゲン受容体拮抗薬
EP3353154B3 (en) 2015-09-25 2022-10-19 Ludwig Institute for Cancer Research Ltd 3-hydroxy-7-(sulfonyl)quinazoline-2,4(1h,3h)-dione and 3-hydroxy-pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives and related compounds as flap-endonuclease 1 (fen-1) inhibitors for use in cancer therapy
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3364984B1 (en) 2015-10-15 2021-11-17 City of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
EP3364956A4 (en) 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. CELASTROL ANALOGUES
EP3763368A1 (en) 2015-10-23 2021-01-13 Sunesis Pharmaceuticals, Inc. Heterocyclic pdk1 inhibitors for use to treat cancer
US11058700B2 (en) 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
CN108603037B (zh) 2015-12-10 2020-11-17 希望之城 细胞穿透花青偶联抗体
PT3394040T (pt) 2015-12-24 2022-03-24 Univ California Reguladores de cftr e seus métodos de uso
KR20180101416A (ko) 2015-12-24 2018-09-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 이용 방법
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物
AU2017205389B2 (en) 2016-01-05 2021-05-20 The Regents Of The University Of California Benzothiazole amphiphiles
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
US11208411B2 (en) 2016-03-17 2021-12-28 The Regents Of The University Of California Compositions and methods for treating parasitic diseases
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
PL3458448T3 (pl) 2016-04-25 2021-12-06 Forma Therapeutics, Inc. Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
US20210323913A1 (en) 2016-04-29 2021-10-21 Board Of Regents, The University Of Texas System Sigma receptor binders
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3023490C (en) 2016-05-12 2021-06-08 Anacor Pharmaceuticals, Inc. Oxaborole esters and uses thereof
JP6853833B2 (ja) 2016-05-26 2021-03-31 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア エストロゲン受容体調節物質の組合せ
ES2940911T3 (es) 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2018013609A2 (en) 2016-07-11 2018-01-18 The Regents The University Of California Synthetic melanin nanoparticles uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
IL264397B2 (en) 2016-07-29 2024-04-01 Rapt Therapeutics Inc Receptor regulators of chemokines and their uses
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
WO2018053035A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted dna demethylation and methylation
CA3036852A1 (en) 2016-09-15 2018-03-22 City Of Hope Dithio etp derivatives
US10849955B2 (en) 2016-09-28 2020-12-01 City Of Hope Methods of treating pancreatic cancer using GPCR antagonists
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
PT3532470T (pt) 2016-10-26 2023-02-28 Rigel Pharmaceuticals Inc Derivados de oxazol para uso como inibidores de irak e método para a sua preparação
CA3040526A1 (en) 2016-10-26 2018-05-03 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
EP3547836B1 (en) 2016-11-30 2024-08-21 University of Southern California A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
AU2017378487B2 (en) 2016-12-15 2022-03-31 The Regents Of The University Of California Compositions and methods for treating cancer
CN110691598A (zh) 2016-12-29 2020-01-14 赛列尼蒂治疗(百慕大)有限公司 金属酶抑制剂化合物
EP3562306A4 (en) 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. METALLOENZYME INHIBITOR COMPOUNDS
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CA3067695A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2019006126A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM
WO2019006371A1 (en) 2017-06-30 2019-01-03 City Of Hope COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
CN111386283A (zh) 2017-09-29 2020-07-07 基因泰克公司 肽抗菌复合物及其使用方法
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
US11040981B2 (en) 2017-10-10 2021-06-22 Syros Pharmaceuticals, Inc. Pyrrolotriazine compounds and methods of inhibiting TAM kinases
WO2019079819A1 (en) 2017-10-20 2019-04-25 City Of Hope COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3704115A1 (en) 2017-11-02 2020-09-09 Calico Life Sciences LLC Modulators of the integrated stress pathway
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
AU2018360847B2 (en) 2017-11-02 2023-07-27 Abbvie Inc. Modulators of the integrated stress pathway
BR112020008836A2 (pt) 2017-11-02 2021-03-30 Calico Life Sciences Llc Moduladores da via de estresse integrada
CN112204012B (zh) 2017-11-02 2023-12-26 卡里科生命科学有限责任公司 整合应激通路的调节剂
SG11202004074TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
TWI838350B (zh) 2017-11-06 2024-04-11 美商瑞佩特治療公司 抗癌劑
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
FI3720438T3 (fi) 2017-12-07 2023-09-01 Amplyx Pharmaceuticals Inc Heterosykli-substituoidut pyridiinistä johdetut antifungaaliset aineet
US11939575B2 (en) 2017-12-19 2024-03-26 City Of Hope Modified tracrRNAs gRNAs, and uses thereof
EP3740207A4 (en) 2018-01-16 2021-10-13 Syros Pharmaceuticals, Inc. CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS
AU2019209475A1 (en) 2018-01-16 2020-08-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
BR112020015056A2 (pt) 2018-01-26 2020-12-08 Rapt Therapeutics, Inc. Moduladores de receptor de quimiocina e usos dos mesmos
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
AU2019234670B2 (en) 2018-03-13 2023-11-23 Takeda Pharmaceutical Company Limited Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
IL278335B1 (en) 2018-05-01 2024-05-01 Revolution Medicines Inc C26-linked rapamycin analogs as MTOR inhibitors
PT3788049T (pt) 2018-05-01 2023-06-07 Revolution Medicines Inc Análogos de rapamicina ligados ac40, c28 e c32 como inbidores de mtor
SG11202010915XA (en) 2018-05-03 2020-12-30 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
SI3788045T1 (sl) 2018-05-03 2023-07-31 Rigel Pharmaceuticals, Inc. Zaviralne spojine RIP1 in postopki njihove izdelave in uporabe
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
AR125425A1 (es) 2018-06-21 2023-07-19 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
EP3810115B1 (en) 2018-06-25 2024-07-17 Basilea Pharmaceutica International AG, Allschwil Pyridine derivatives substituted by heterocyclic ring and amino group
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
CN113396150B (zh) 2018-11-01 2024-03-12 凌科药业(杭州)有限公司 三环janus激酶1抑制剂及其组合物和方法
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
CA3131894A1 (en) 2019-03-14 2020-09-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
BR112021021703A2 (pt) 2019-04-30 2022-04-19 Abbvie Inc Cicloalquilas substituídas como moduladores da via de estresse integrada
US10973780B2 (en) 2019-05-15 2021-04-13 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
WO2020252487A1 (en) 2019-06-14 2020-12-17 Children's Hospital Medical Center Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
JP2022543843A (ja) 2019-08-08 2022-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
AU2020335903A1 (en) 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
EP4025575A1 (en) 2019-09-06 2022-07-13 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
MX2022002718A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos.
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
JP2022548665A (ja) 2019-09-18 2022-11-21 ノバルティス アーゲー Ｎｋｇ２ｄ融合タンパク質及びその使用
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
WO2021092336A1 (en) 2019-11-07 2021-05-14 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 inhibitory compounds
CA3158521A1 (en) 2019-11-13 2021-05-20 Rapt Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
CA3162069A1 (en) 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof
IL297492A (en) 2020-05-19 2022-12-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
WO2022038170A1 (en) 2020-08-18 2022-02-24 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
PE20231656A1 (es) 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
CA3198795A1 (en) 2020-11-18 2022-05-27 Jeffrey Becker Complexing agent salt formulations of pharmaceutical compounds
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022197756A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors
EP4308564A1 (en) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
EP4308229A1 (en) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein
EP4308230A1 (en) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein
EP4308227A1 (en) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Imidazopyridinyl inhibitors of plasma kallikrein
AU2023222126A1 (en) 2022-02-15 2024-08-08 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
WO2023156450A1 (en) 2022-02-15 2023-08-24 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
US20230312568A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors
WO2023196432A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN114504550B (zh) * 2022-04-18 2022-08-19 中山大学中山眼科中心 一种包含甲硝唑的眼用凝胶及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4565821A (en) * 1983-03-21 1986-01-21 The Texas A&M University System Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones
GB8318403D0 (en) * 1983-07-07 1983-08-10 Sutherland I W Gel-forming polysaccharides
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
GB8628068D0 (en) * 1986-11-24 1986-12-31 Unilever Plc Aqueous gel comprising carrageenan
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
JPH02291619A (ja) * 1989-04-28 1990-12-03 Mitsubishi Kasei Corp 透明タッチパネル
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
JPH0458418A (ja) * 1990-06-26 1992-02-25 Hitachi Aic Inc タッチパネル

Also Published As

Publication number Publication date
JPH06116137A (ja) 1994-04-26
EP0495421B1 (en) 1996-08-21
DE69212850D1 (de) 1996-09-26
ATE141502T1 (de) 1996-09-15
CA2059403C (en) 1999-03-09
CA2059403A1 (en) 1992-07-16
DE69212850T2 (de) 1997-03-06
EP0495421A1 (en) 1992-07-22
US5403841A (en) 1995-04-04
JP2594486B2 (ja) 1997-03-26

Similar Documents

Publication Publication Date Title
DK0495421T3 (da) Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
DK54390A (da) Okularcyklosporinpraeparat
IT1273011B (it) Preparato oftalmico per l'uso come lacrima artificiale
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
Fisher et al. Allergic contact sensitivity to benzalkonium chloride: cutaneous, ophthalmic, and general medical implications
LV5725A4 (lv) Gelu veidojosa oftalmologiska kompozicija
ATE80043T1 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
BR9702362A (pt) Novas fomrulações lìquidas estáveis à base de paracetamol e seu modo de preparação.
IT1233108B (it) Dispositivo per la correzione delle anomalie di rifrazione dell'occhio.
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
NO940160D0 (no) Oeyepreparater inneholdende oxicam eller oxicamderivater
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
ATE401394T1 (de) Verbesserte dnase flüssige lösungen
KR880001290A (ko) β-차단제 및 필로카르핀-함유 제제
SE9302203D0 (sv) Composition for ophthalmic use
RU2073523C1 (ru) Препарат для лечения ожоговой болезни глаз i-iy степеней
KR930702015A (ko) 각막 장해 치료제
FR2661091B1 (fr) Utilisation de l'hexetidine ou de ses derives ou sels pour la preparation d'une composition pharmaceutique a usage ophtalmologique.
IT1241928B (it) Composizione oftalmica per l'uso nel mantenimento della midriasi oculare
EP0396169A2 (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.
BG96092A (bg) Тиенотиопиранови сулфонамидни производни и приложението им в офталмологични препарати
ATE87465T1 (de) Neues arzneimittel mit antiallergischer wirkung und verzoegerter wirkstofffreigabe.
IT8348873A0 (it) Retinoprotettore per la terapia del le emorragie intraoculari, delle distrofie corioretiniche, di carattere miopico, delle distropie eredita rie della retina e delle scottature della retina, nonche' per la cura profilattica delle lesioni dovute alla coagulazione a laser
RU94025455A (ru) Способ хирургической коррекции миопического астигматизма высокой степени на артифакичном глазу